Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
Develops gene therapies for cardiovascular and CNS diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a single gene fix a fatal heart condition? a trial aims to find out
⭐️ CURE ⭐️ Recruiting nowThis phase 2 trial tests whether a single dose of LX2006 gene therapy can improve heart muscle thickening and damage in people with Friedreich ataxia, a genetic disorder that often leads to life-threatening cardiomyopathy. Participants aged 6 and older with confirmed heart enlarg…
Phase: PHASE2 • Sponsor: Lexeo Therapeutics • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
New study tracks heart disease in rare genetic disorder
Knowledge-focused Recruiting nowThis study follows 65 people with Friedreich ataxia who also have a thickened heart muscle (cardiomyopathy). Researchers will measure changes in heart structure over time using imaging. The goal is to better understand how heart disease progresses in this condition, which could h…
Sponsor: Lexeo Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC